MedTrace Logo

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

NCT07127315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-08-17

No results posted yet for this study

Summary

The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.

Conditions

Interventions

DRUG

Gonadotropin-releasing hormone agonist

Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.

DRUG

Chemotherapy

Patients received chemotherapy alone.

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-06-01
Completion
2024-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07127315 on ClinicalTrials.gov